Maintaining Nonsmoking
Public ClinicalTrials.gov record NCT01162239. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The research is based on a chronic disorder model of cigarette smoking which suggests that long-term treatment targeted to prevent relapse may be useful. Based on this model, the investigators have developed a relapse prevention treatment to intervene on five areas important in relapse prevention, including fluctuating motivation, depression, withdrawal, weight gain, and social support. This treatment protocol has produced high long-term abstinence rates when implemented in a clinical research setting. The current study will evaluate the treatment model when implemented in a medical outpatient setting.
Study identification
- NCT ID
- NCT01162239
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 216 participants
Conditions and interventions
Conditions
Interventions
- Varenicline Drug
- Initial Individual counseling Behavioral
- Check-ins with medical staff Behavioral
- Extended Individual Counseling - Health Model Behavioral
- Extended Individual Counseling - Relapse Prevention Model Behavioral
Drug · Behavioral
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2010
- Primary completion
- May 31, 2016
- Completion
- May 31, 2016
- Last update posted
- Nov 11, 2020
2010 – 2016
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Francisco | San Francisco | California | 94143 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Nicotine Dependence trials
Other public records listing Nicotine Dependence. Sorted by last update posted; newest first. Not a recommendation.
- NCT07789496: Quit With Sense: Using Mindful Smoking and Wearable Device for Smoking Cessation Not yet recruiting
- NCT03999099: Targeting Orexin to Treat Nicotine Dependence Active, not recruiting
- NCT01782599: Electronic Cigarettes and Reactivity to Smoking Cues Active, not recruiting
- NCT07698470: Brain/Craving Response to Smoking Cues After Oral Nicotine Pouch Use Recruiting
- NCT07145866: Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study) Recruiting
- NCT07694492: Feasibility of a Medical-Legal Partnership Model to Connect Coal Miners QuitAid Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01162239, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 11, 2020 · Synced Sep 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01162239 live on ClinicalTrials.gov.